Boston Scientific Receivables

Boston Scientific (BSX-PA) currently reports a receivables of $3B as of June 2026. That compares with $2.8B in the prior-year period — up 8.3% year over year. Use the charts on this page to explore Boston Scientific's receivables history and peer comparisons.

Boston Scientific's receivables increased from $2.8B to $3B — a 8.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Boston Scientific reported $3B in receivables as of June 2026. That compares with $2.8B in the prior-year period — up 8.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $3B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Boston Scientific, and consider following BSX-PA for alerts when major investors trade the stock.

Boston Scientific is classified in the Healthcare sector. On receivables, it currently shows $3B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BSX-PA with unrelated industries.